Sanofi has been particularly busy on the deal making front in March 2022, entering into a number of key collaboration and licensing agreements in an attempt to bolster its therapeutic antibody pipeline. The company started the month of March by announcing its US$2.5 B deal with Adagene to access the latter’s antibody masking SAFEbody® technology platform. Only a few weeks later, Sanofi committed up to US$6 B to access IGM Biosciences’ IgM antibody technology platform for detecting agonists against three targets in oncology, and three in immunology/inflammation.